- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05726136
Provocation liquidienne et volume plasmatique, pendant la chirurgie (FC-VE)
Comparaison de l'albumine et de la solution de Ringer pour l'optimisation du volume plasmatique et de l'hémodynamique pendant la chirurgie laparoscopique.
A short bolus infusion of fluid, called "fluid challenge" is commonly recommended for fluid treatment during longer surgery. However a prolonged increase of the blood volume is a prerequisite to recommend the technique. The purpose with the study is to examine the plasma expanding effect of three different fluid challenge strategies (acetated Ringers 4 ml/kg body weight, albumin 5% 4 ml/kg body weight or albumin 20% 1 ml/kg body weight), using hemoglobin as a dilution indicator.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
60 patients scheduled for laparoscopic abdominal surgery, with a duration exceeding 90 minutes will be included in the study. These are randomized to three different groups (20 in each groups): The first group of patients will receive boluses of acetated Ringers 4 ml/kg body weight. The second albumin 4 ml/kg body weight and the third group albumin 20% 1 ml/kg body weight.
Hemoglobin, albumin and colloid osmotic pressure (COP) is sampled the day before surgery and in the morning directly prior to the anesthesia. Bioimpedance, urine osmolality and urine-creatinin are also measured. After induction of surgery a Cardio Q probe is inserted threw the nose into the esophagus, for circulatory measurements. Initial/baseline blood samples are taken after insufflation of carbon dioxide to the abdomen. Before every bolus of fluid and 5, (10), 15, 20, 30, 40, (50) and (60) minutes new blood samples are taken for determination of hemoglobin, albumin and COP. Artery blood gases are sampled 15 minutes after every infusion or depending on the clinical need.
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
Östergötland County
-
Norrköping, Östergötland County, Suède, 60379
- Vrinnevi Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Written consent to participate in the study
- For women: relevant contraceptive, menopausal or a negative pregnancy test.
- ASA category I to III
- Laparoscopic abdominal surgery, with a duration of at least 90 minutes.
- 18 to 85 years
Exclusion Criteria:
- Patients with known cardiac failure
- <18 or >85 years
- known allergy to albumin
- extracellular hyperhydration or hypervolemia
- kidney failure
- pregnancy or planned pregnancy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: acetated Ringers
The circulatory effect of a bolus infusion with 4 ml/kg body weight of acetated Ringers will be studied. If cardiac output increase with 10% a second bolus will be infused and further studied. |
After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first fluid bolus is infused. Circulatory and volume effects are studied. If cardiac output increase a second bolus is infused and studied.
Autres noms:
|
|
Expérimental: albumin 5%
The circulatory effect of a bolus infusion with 4 ml/kg body weight of Albumin 5% will be studied. If cardiac output increases with 10% a second bolus will be infused and further studied. |
After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
Autres noms:
|
|
Expérimental: albumin 20%
The circulatory effect of a bolus infusion with 1 ml/kg body weight of Albumin 20% will be studied. If cardiac output increase with 10% a second bolus will be infused and further studied. |
After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Plasma volume expansion after a fluid bolus
Délai: 60 minutes after an intravenous fluid bolus
|
Plasma volume using hemoglobin as an indicator of dilution |
60 minutes after an intravenous fluid bolus
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fluid Balance
Délai: 18 to 24 hours
|
Calculations of fluid balance |
18 to 24 hours
|
|
Stroke Volume
Délai: 60 minutes after an intravenous fluid bolus
|
Change in stroke volume, measured with Cardio Q (oesophageal Doppler monitoring (ODM)) |
60 minutes after an intravenous fluid bolus
|
|
Arterial Blood Pressure
Délai: 60 minutes after an intravenous fluid bolus
|
Mean Arterial Pressure, measured with an arterial line. |
60 minutes after an intravenous fluid bolus
|
|
Heart Rate
Délai: 60 minutes after an intravenous fluid bolus
|
Heart rate, measured with ECG and pulseoximeter. |
60 minutes after an intravenous fluid bolus
|
|
Bioimpedance
Délai: 18 to 24 hours
|
Bioimpedance measures, resistance and impedance converted to volume of body fluid compartments. |
18 to 24 hours
|
|
Serum Creatinin
Délai: 18 to 24 hours
|
Serum Creatinin as a measure of kidney function |
18 to 24 hours
|
|
arterial pH
Délai: 60 minutes after an intravenous fluid bolus
|
Influence of a fluid bolus on arterial blood gases |
60 minutes after an intravenous fluid bolus
|
|
arterial Base Excess
Délai: 60 minutes after an intravenous fluid bolus
|
Influence of a fluid bolus on arterial blood gases |
60 minutes after an intravenous fluid bolus
|
|
arterial serum sodium
Délai: 60 minutes after an intravenous fluid bolus
|
Influence of a fluid bolus on Sodium concentration |
60 minutes after an intravenous fluid bolus
|
|
arterial serum chloride
Délai: 60 minutes after an intravenous fluid bolus
|
Influence of a fluid bolus on Chloride concentrations |
60 minutes after an intravenous fluid bolus
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Joachim Zdolsek, MD PhD, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Tumeurs urogénitales
- Tumeurs par site
- Maladies urogénitales masculines
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies intestinales
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies gastro-intestinales
- Tumeurs intestinales
- Maladies rectales
- Maladies du côlon
- Tumeurs
- Tumeurs colorectales
- Tumeurs urologiques
- Acides aminés, peptides et protéines
- Protéines
- Albumines
- Acétate de la sonnerie
- zidovudine 5'-monophosphate-mannose-albumin conjugate
- galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
Autres numéros d'identification d'étude
- FC-VE
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual de-identified results will be shared, when results are published.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .